-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $34

Benzinga·11/10/2026 13:50:36
Listen to the news
Guggenheim analyst Subbu Nambi maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $32 to $34.